A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
overreaction
glennwhiteside, You are right! I had 100 shares of Amylin. So? I bought 100 more the day it dropped.
It still has a big advantage over competition ( a moat I think in its once a week injection) Eli Lily has the European market which could approve Bydureon much sooner than the U.S.
sometimes I am right! not as often as I'd like though...